RIVERVEST VENTURE MANAGEMENT LLC
Q3 2023 Form 13-F
ST. LOUIS, MISSOURI
CIK 0001812549
· Institutional investment manager
$40.4M Reported Value Total
Reported value
$40.4M
Quarter over quarter
-16.6%
Holdings
5
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Sivan Weitzman
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2023 13F record
Q3 2023 13F filing summary
| Period of report | September 30, 2023 |
|---|---|
| Filed | October 30, 2023 |
| Form | 13F-HR |
| Reported value | $40.4M |
| Positions | 5 |
| Change in reported value | -55.2% |
| New positions | 0 |
| Exited positions | 1 |
| Position turnover | 16.7% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2024 13F
Filed Oct 30, 2024
|
3 | $6.8M |
|
Q2 2024 13F
Filed Jul 24, 2024
|
4 | $6.8M |
|
Q1 2024 13F
Filed May 8, 2024
|
4 | $8.1M |
|
Q4 2023 13F
Filed Feb 12, 2024
|
5 | $27.1M |
|
Q3 2023 13F
Filed Oct 30, 2023
|
5 | $40.4M |
|
Q2 2023 13F
Filed Aug 7, 2023
|
6 | $90.2M |
|
Q1 2023 13F
Filed Apr 27, 2023
|
6 | $86.4M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
6 | $85.7M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
6 | $86.1M |
|
Q2 2022 13F
Filed Aug 10, 2022
|
6 | $68.0M |
|
Q1 2022 13F
Filed May 2, 2022
|
6 | $97.4M |
|
Q4 2021 13F
Filed Feb 7, 2022
|
6 | $140.2M |
|
Q3 2021 13F
Filed Nov 12, 2021
|
5 | $595.6M |
|
Q2 2021 13F
Filed Aug 11, 2021
|
5 | $511.6M |
|
Q1 2021 13F
Filed Aug 11, 2021
|
4 | $649.3M |
|
Q4 2020 13F
Filed Aug 11, 2021
|
5 | $910.3M |
Top 5 holdings · Q3 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RPHM Reneo Pharmaceuticals, Inc. | $19.3M | 47.73% |
| 2 | ALLK Allakos, Inc. | $11.3M | 28.0% |
| 3 | SPRB Spruce Bioscience, Inc. | $6.6M | 16.41% |
| 4 | XLO Xilio Therapeutics, Inc. | $3.0M | 7.52% |
| 5 | VAPO Vapotherm, Inc. | $133.0K | 0.33% |
Values as reported on the Q3 2023 Form 13F. Every position is in the holdings table below.